Your browser doesn't support javascript.
loading
Targeting cancer glycosylation repolarizes tumor-associated macrophages allowing effective immune checkpoint blockade.
Stanczak, Michal A; Rodrigues Mantuano, Natalia; Kirchhammer, Nicole; Sanin, David E; Jacob, Francis; Coelho, Ricardo; Everest-Dass, Arun V; Wang, Jinyu; Trefny, Marcel P; Monaco, Gianni; Bärenwaldt, Anne; Gray, Melissa A; Petrone, Adam; Kashyap, Abhishek S; Glatz, Katharina; Kasenda, Benjamin; Normington, Karl; Broderick, James; Peng, Li; Pearce, Oliver M T; Pearce, Erika L; Bertozzi, Carolyn R; Zippelius, Alfred; Läubli, Heinz.
Afiliación
  • Stanczak MA; Department of Biomedicine, University Hospital and University of Basel, 4031 Basel, Switzerland.
  • Rodrigues Mantuano N; Bloomberg-Kimmel Institute for Cancer Immunotherapy at Johns Hopkins, Baltimore, MD 21287, USA.
  • Kirchhammer N; Max Planck Institute of Immunobiology and Epigenetics, 79108 Freiburg, Germany.
  • Sanin DE; Department of Biomedicine, University Hospital and University of Basel, 4031 Basel, Switzerland.
  • Jacob F; Department of Biomedicine, University Hospital and University of Basel, 4031 Basel, Switzerland.
  • Coelho R; Max Planck Institute of Immunobiology and Epigenetics, 79108 Freiburg, Germany.
  • Everest-Dass AV; Department of Biomedicine, University Hospital and University of Basel, 4031 Basel, Switzerland.
  • Wang J; Department of Biomedicine, University Hospital and University of Basel, 4031 Basel, Switzerland.
  • Trefny MP; Institute for Glycomics, Griffith University, Gold Coast Campus, Gold Coast QLD4222, Australia.
  • Monaco G; Department of Biomedicine, University Hospital and University of Basel, 4031 Basel, Switzerland.
  • Bärenwaldt A; Department of Biomedicine, University Hospital and University of Basel, 4031 Basel, Switzerland.
  • Gray MA; Department of Biomedicine, University Hospital and University of Basel, 4031 Basel, Switzerland.
  • Petrone A; Department of Biomedicine, University Hospital and University of Basel, 4031 Basel, Switzerland.
  • Kashyap AS; Department of Chemistry, Stanford ChEM-H, and Howard Hughes Medical Institute, Stanford University, Stanford, CA 94305, USA.
  • Glatz K; Palleon Pharmaceuticals, Waltham, MA 02451, USA.
  • Kasenda B; Department of Biomedicine, University Hospital and University of Basel, 4031 Basel, Switzerland.
  • Normington K; Institute of Pathology, University Hospital Basel, 4031 Basel, Switzerland.
  • Broderick J; Division of Oncology, Department of Theragnostics, University Hospital Basel, 4031 Basel, Switzerland.
  • Peng L; Palleon Pharmaceuticals, Waltham, MA 02451, USA.
  • Pearce OMT; Palleon Pharmaceuticals, Waltham, MA 02451, USA.
  • Pearce EL; Palleon Pharmaceuticals, Waltham, MA 02451, USA.
  • Bertozzi CR; Centre for Tumour Microenvironment, Barts Cancer Institute, Queen Mary University, London EC1M 6BQ, UK.
  • Zippelius A; Bloomberg-Kimmel Institute for Cancer Immunotherapy at Johns Hopkins, Baltimore, MD 21287, USA.
  • Läubli H; Max Planck Institute of Immunobiology and Epigenetics, 79108 Freiburg, Germany.
Sci Transl Med ; 14(669): eabj1270, 2022 11 02.
Article en En | MEDLINE | ID: mdl-36322632

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Inhibidores de Puntos de Control Inmunológico / Neoplasias Tipo de estudio: Risk_factors_studies Límite: Animals / Humans Idioma: En Revista: Sci Transl Med Asunto de la revista: CIENCIA / MEDICINA Año: 2022 Tipo del documento: Article País de afiliación: Suiza Pais de publicación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Inhibidores de Puntos de Control Inmunológico / Neoplasias Tipo de estudio: Risk_factors_studies Límite: Animals / Humans Idioma: En Revista: Sci Transl Med Asunto de la revista: CIENCIA / MEDICINA Año: 2022 Tipo del documento: Article País de afiliación: Suiza Pais de publicación: Estados Unidos